We have read with great enthusiasm the recently published article entitled ''Use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabetics" by Ferraz et al. 1 . We congratulate the authors for their lightening study. In that well-designed study, Ferraz and coworkers tried to evaluate the effect of preoperative intravitreal bevacizumab (IVB) or triamcinolone (IVT) on the rate of early postvitrectomy hemorrhage in proliferative diabetic retinopathy (PDR). They concluded that intravitreal injection of bevacizumab 1 week before vitrectomy seems to reduce the incidence of early postvitrectomy hemorrhage in diabetic patients. We think that the factors which can affect the vitreous hemorhage (VH) after vitrectomy in diabetics are not completely discussed in this study and we would like to make some contributions about this.
